SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations - - Dosing of the first participant in the Phase 1b FALCON trial has been completed, with initial data expected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback